Background. There is a lack of clear benefit and a potential risk of bleeding with direct oral anticoagulant (DOAC) use in chronic kidney disease (CKD) and dialysis patients with atrial fibrillation. The objective of this study was to evaluate how treatment with DOACs affects stroke and bleeding outcomes compared with warfarin or aspirin. Methods. We conducted a systematic review of randomized controlled trials, cohort studies and case series, and searched electronic databases from 1946 to 2017. Studies evaluating stroke and bleeding outcomes with DOAC use in CKD and dialysis patients were included. Results. From 8008 studies, 10 met the inclusion criteria. For moderate CKD patients (estimated glomerular filtration rate <60 mL/min/1.73 m
I N T R O D U C T I O N
Atrial fibrillation (AF) is highly prevalent (13-27%) in chronic kidney disease (CKD) [1] and in those on long-term hemodialysis (HD) [2] . Stroke is a common complication of AF; CKD patients and patients on HD with AF have additional risk factors for stroke or systemic embolism (SE) [3] due to vascular co-morbidities, HD treatment, advanced age and diabetes [4] . In addition, they are at an increased risk of major bleeding due to uremic platelet impairment [5] . The use of anticoagulants further increases bleeding risk in CKD and HD patients [5] by $10 times compared with non-CKD patients on warfarin [6] .
In the general population, warfarin was previously the elected agent for stroke prevention in AF patients. However, with evidence of direct oral anticoagulants (DOACs) showing equivalent or better stroke and bleeding outcomes compared to warfarin, while also requiring less frequent monitoring to maintain anticoagulation and a more favorable pharmacological profile [7] [8] [9] [10] [11] , DOACs are seemingly a more appealing therapeutic alternative in non-CKD or patients with mild renal impairment [12] . In the moderate CKD and HD population, the same data do not exist [12, 13] ; prescribers are reluctant to use DOACs and warfarin is commonly prescribed, despite the high bleeding risk [5] , lack of efficacy data and controversial opinion between international guidelines [14] [15] [16] .
Randomized controlled trials (RCTs) studying the DOACs in AF all demonstrated non-inferiority to warfarin for stroke or SE; however, these studies excluded patients on HD and those with a creatinine clearance (CrCl) of <25-30 mL/ min [7] [8] [9] [10] 13] . Therefore, given the lack of clear benefits and the potential risks of bleeding with DOACs versus warfarin use in CKD and HD patients, the objective of this systematic review was to evaluate how treatment with DOACs affects stroke and bleeding outcomes compared with warfarin or aspirin in this specific population.
M A T E R I A L S A N D M E T H O D S

Information sources and search strategy
The review protocol was registered with the international prospective register of systematic reviews (http://www.crd.york. ac.uk/PROSPERO; registration number 42017067199).
The following databases were searched under the guidance of a research librarian: MEDLINE 27 April 2017) . Literature search strategies were developed using MeSH and keywords related to the currently available DOACs, apixaban, rivaroxaban, edoxaban, dabigatran, anticoagulants, hemodialysis, dialysis, CKD, kidney disease, renal insufficiency, ESRD and their respective combinations. The language was limited to English. Search for gray literature was performed using the World Health Organization (WHO) website, Canadian Agency for Drugs and Technologies in Health (CADTH), US Federal Science (science.gov), science.org, Thrombosis Canada and Google Scholar to identify relevant studies. The exact search strategy is outlined in Supplementary Material Table S1 . Two study personnel (J.F. and J.M.) independently reviewed titles and abstracts, and the full-text review was conducted on studies that met the eligibility criteria. Another member of the research team (M.B.) resolved any disputes.
Study selection
RCTs and observational studies including prospective or retrospective cohort studies and case series were included in the search. Studies with <10 subjects, case reports, review articles, editorials, guidelines and non-English studies were excluded. Furthermore, only studies that included adult patients (>18 years old), on one of the DOACs for AF and who had concomitant CKD, with estimated glomerular filtration rate (eGFR) 60 mL/min or on dialysis, were included. Only studies that examined, reported and compared any type of stroke or bleeding outcomes in patients on DOACs against patients not on DOACs were included.
Data extraction
Two study personnel, J.F. and J.M., screened the search results according to the eligibility criteria. J.F., P.P. and S.S. extracted data from the included studies using a data extraction form in Microsoft Excel. Extracted data included relevant patient characteristics (e.g. age, renal function, CHADS 2 or CHA 2 DS 2 -VASc score), methods (e.g. study design, duration of follow-up, data collection method) and interventions (treatment and comparison group) and outcomes. For efficacy outcomes, the type and incidence/rate/risk of stroke was extracted. For safety outcomes, data about the severity, definition and incidence/rate/risk of bleeding or mortality was extracted. Any discrepancies were resolved by discussion and consensus.
Risk of bias in individual studies
The quality of the three cohort studies and one case-control study included in the review was assessed using the NewcastleOttawa Scale (NOS) [17] . NOS ranks studies based on three categories: the selection of study groups, the comparability of the groups and the ascertainment of outcome or exposure of interest. The quality is assessed based on a star system such that there can be a maximum of nine stars awarded: four for selection of study groups, two for comparability of study groups and three for outcome or exposure ascertainment; a higher number of stars indicates a higher quality study [17] . The six RCTs included were assessed using the Cochrane Risk of Bias (ROB) tool [18] . The ROB tool assesses studies based on seven domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other sources of bias. Each domain is assessed as having high, low or unclear ROB [18] . P.P., J.F. and S.S. independently assessed the quality of included studies using NOS for cohort and case-control studies, and Cochrane ROB for RCTs.
R E S U L T S
Study yield
The initial search yielded 8008 articles. After removing duplicates, 6486 titles and abstracts were initially screened, 6445 articles were excluded for being irrelevant to DOAC use in dialysis (and synonyms) and CKD (eGFR 60 mL/min), or were reviews, editorials, case reports or guidelines. A total of 41 articles were relevant to DOAC use in CKD patients with AF. Of these, 19 studies were not RCTs, cohort or case series studies, 5 articles had study groups without AF, or were not CKD or HD patients, 3 articles had a comparator other than warfarin, aspirin or placebo, 2 studies had outcomes measured that were not stroke or bleeding, 1 study had an intervention other than DOAC, and finally 1 article was a study still in progress. The remaining 10 articles met the inclusion criteria. The flow of study selection is described in Figure 1 .
Study characteristics
An overview of selected study characteristics such as study design, duration of follow-up, renal function and age is provided in Table 1 . There were six RCTs [22] [23] [24] [25] [26] 28] , all of which were post-analysis of the CKD subgroup in the RCTs of the DOACs in AF. There were three retrospective cohort studies and one case-control study. Study samples' sizes ranged from 10 to 1474 patients exposed to a DOAC. In terms of renal function, one study examined HD patients only [19] , one study included patients with CrCl 25 mL/min or on dialysis [20] , two studies included patients with CKD (eGFR <60 mL/min) [27, 29] and six studies included patients with Stage 3 CKD (eGFR 30-59 mL/min, CrCl 30-49 mL/min, eGFR 25-50 mL/ min) [22] [23] [24] [25] [26] 28] . Four studies used the Cockcroft-Gault equation to estimate renal function [20, 24, 26, 28] , two studies used the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [21, 29] , while two studies used both equations [23, 25] . One study did not report how renal function was estimated [27] , and another study included only HD patients, therefore renal function estimated was not needed. Studies reported CHADS 2 or CHA 2 DS 2 -VASc scores of 2.2-6.1, with the exception of two studies that did not report this value [25, 27] . Mean follow-up ranged from 0.08 to 2.8 years.
One study was conducted in Canada [27] , two studies were conducted in the United States [19, 21] , six were multicenter, international studies [22] [23] [24] [25] [26] 28] and one study was conducted in South Korea [29] . Studies were heterogeneous with respect to definitions of bleeding and stroke outcomes. A metaanalysis was not conducted due to the heterogeneity of the studies.
Quality assessment
Assessment of the quality of the three cohort studies and one case-control study using the NOS resulted in high-quality studies, with all studies receiving seven or eight stars. For the six RCT studies included, Cochrane ROB tool resulted in one study with a high risk of bias and five studies with a low risk of bias (See Supplementary Material Table S2 ).
Stroke outcomes
An overview of the definition, incidences and hazard ratios (HRs) of stroke outcomes obtained from each trial is provided in Table 2 . Six studies reported ischemic/hemorrhagic stroke or SE [22] [23] [24] [25] [26] 28] , one study reported ischemic stroke [20] , one disclosed new-onset strokes [29] , one reported embolic stroke and arterial embolism [19] and one study did not report stroke outcomes, only bleeding outcomes [27] . Systematic review-DOACs in CKD
Apixaban stroke outcomes
Two studies included in the systematic review compared apixaban with warfarin [20, 23] , and one study compared apixaban with aspirin [21] . Only one of these three studies included patients with CrCl <25 mL/min and dialysis patients [20] . One study comparing apixaban with warfarin in moderate CKD patients (eGFR 25-50 mL/min) showed that apixaban had no significant difference in stroke or SE compared to warfarin using the Cockcroft-Gault estimation of eGFR (95% CI 0.55-1.14) [23] . In this same study, apixaban significantly reduced stroke or SE compared with warfarin using CKD-EPI's approximation of eGFR (95% CI 0.39-0.94) [23] . When comparing apixaban to aspirin in moderate CKD patients (eGFR 30-59 mL/min), apixaban was associated with a lower ischemic/hemorrhagic stroke or SE incidence rate (1.8% per year) compared with aspirin (5.6% per year) (95% CI 0.18-0.55) [21] . There was no difference in stroke outcomes between apixaban and warfarin groups for dialysis patients, as only four patients in both groups experienced an ischemic stroke; however, the study had a small sample size and was therefore underpowered to examine this endpoint [20] .
Dabigatran stroke outcomes
Two studies compared dabigatran with warfarin for stroke outcomes: one cohort study comprised HD patients [19] and one subgroup analysis of the RE-LY trial in patients with eGFR 30-50 mL/min [25] . In the RE-LY trial subgroup analysis, there was no significant difference of ischemic or hemorrhagic stroke or SE compared to warfarin for dabigatran 110 mg twice daily (HR 0.78, 95% CI 0.51-1.21) [25] . However, the dabigatran 150 mg twice daily treatment arm did show reduced risk of ischemic/hemorrhagic stroke or SE (1.21% per year) compared with warfarin (2.17% per year) in moderate CKD patients (HR 0.55, 95% CI 0.34-0.89) [25] . For HD patients, there was no statistically significant difference for embolic stroke and arterial embolism between dabigatran and warfarin (95% CI 0.97-2.99) [19] ; however, the study had short follow-up times (0.48 years for warfarin, 0.44 years for dabigatran) [19] and was thus underpowered to examine this endpoint.
Rivaroxaban stroke outcomes
The three studies included that examined rivaroxaban compared with warfarin in CKD patients with AF showed no significant difference in ischemic or hemorrhagic stroke or SE [26, 28] or embolic stroke and arterial embolism [19] . In the two studies that were ROCKET-AF trial [26, 28] subgroup analyses of the ROCKET-AF trial in patients with CrCl 30-49 mL/min, there was no difference in ischemic or hemorrhagic stroke or SE (HR 0.84, 95% CI 0.57-1.23 [26] ; HR 0.82, 95% CI 0.25-2.69 [28] ). HD patients on rivaroxaban also demonstrated no significant difference in the incidence of embolic stroke and arterial embolism compared to warfarin [relative risk (RR) 1.80, 95% CI 0.89-3.64]; however, this cohort study had a short duration of followup (0.48 years for warfarin, 0.30 years for rivaroxaban) [19] .
Edoxaban stroke outcomes
In the subgroup analysis of ENGAGE AF-TIMI 48 trial in patients with CrCl 30-50 mL/min, edoxaban showed no significant
Bleeding outcomes
An overview of the definition, incidences and HRs of bleeding outcomes obtained from each trial is provided in Table 3 . Six studies [20, 21, 23, 24, 26, 29] defined major bleeding as per International Society on Thrombosis and Haemostasis (ISTH) definition [30] , two studies defined major bleeding based on a modified ISTH definition [25, 28] , and one study defined major bleeding as a hemorrhagic event resulting in hospitalization or death [19] . Another study defined a major hemorrhage as a hospital presentation to the emergency room or hospital admission for hemorrhage [27] .
Apixaban bleeding outcomes
In the subgroup analysis of the ARISTOLE trial, in patients with eGFR 25-50 mL/min, apixaban had a lower incidence of major bleeding (3.28% per year) than warfarin (6.78% per year) (HR 0.48, 95% CI 0.37-0.64), and a significant reduction in allcause mortality using the CKD-EPI equation (HR 0.78, 95% CI 0.63-0.96) [23] , with no difference in all-cause mortality using Cockcroft-Gault (HR 0.86, 95% CI 0.70-1.05) [23] . In the subgroup analysis of the AVERROES trial, CKD patients (eGFR 30-59 mL/min) on apixaban also demonstrated no significant difference in major bleeding (HR 1.2, 95% CI 0.65-2.1) or allcause mortality (HR 0.86, 95% CI 0.61-1.2) compared to aspirin [21] . The cohort study that included patients with CrCl 25 mL/min and dialysis patients showed no statistically significant difference of major bleeding and composite bleeding outcomes [20] ; however, the study had a small sample size.
Dabigatran bleeding outcomes
There was no significant difference in a subgroup analysis of the RE-LY trial with moderate CKD patients with respect to major bleeding, life-threatening bleeding and all-cause mortality; however, dabigatran 150 mg twice daily was associated with a lower risk of intracranial bleeding with HRs of 0.31 and 0.38 using the Cockcroft-Gault and CKD-EPI equations [25] . Dabigatran 110 mg twice daily demonstrated a reduced risk of intracranial bleeding compared with warfarin using the Cockcroft-Gault equation (HR 0.40, 95% CI 0.20-0.80); however, no difference was seen using the CKD-EPI equation (HR 0.45, 95% CI 0.19-1.04) [25] . In the case-control study, there was no statistically significant difference in major hemorrhagic events with dabigatran exposure compared with warfarin exposure [27] .
HD patients had a higher risk of major bleeding (RR 1.76, 95% CI 1.44-2.15) and no significant difference in minor bleeding (RR 1.10, 95% CI 0.93-1.29) with dabigatran compared to warfarin [19] . Mortality as a result of bleeding was higher in the dabigatran group for HD patents, 19.2 deaths per 100 patientyears, compared with 10.2 deaths per 100 patient-years in the warfarin group [19] ; it is not reported whether this difference was statistically significant or not. Higher risk of major bleeding with dabigatran was consistent in subsequent sensitivity analyses where patients were matched based on 20 different clinical Hori et al. [28] (Sub-analysis of J-ROCKET AF Systematic review-DOACs in CKD parameters [19] . Dabigatran still showed an increased risk of major bleeding when compared with patients on warfarin who had >60% of their International Normalized Ratio (INR) readings between 2 and 3 [19] .
Rivaroxaban bleeding outcomes
Subgroup analysis of the ROCKET-AF trial and J-ROCKET AF trial in CKD patients (CrCl 30-49 mL/min) showed no significant difference in the incidence of major bleeding and the composite of major bleeding and non-major, clinically relevant bleeding between rivaroxaban and warfarin [26, 28] . Also, there was no significant difference in death caused by a bleed with rivaroxaban (0.55% per year) versus warfarin (0.56% per year) (HR 1.04, 95% CI 0.07-16.7) [28] . In the case-control study, there was statistically no significant difference in major hemorrhagic events with rivaroxaban exposure compared to warfarin exposure [27] .
In HD patients, rivaroxaban was associated with a higher risk of major bleeding (RR 1.45, 95% CI 1.09-1.93) and minor bleeding (RR 1.36, 95% CI 1.12-1.64) compared with warfarin [19] . Rivaroxaban group had a higher incidence of mortality as a result of bleeding with 16.2 deaths per 100 patient-years compared with 10.2 deaths per 100 patient-years in the warfarin group, but it was not reported whether this difference was statistically significant [19] . In subsequent sensitivity analysis, when rivaroxaban patients were matched to warfarin on 20 clinical parameters, rivaroxaban trended towards a higher risk of major bleeding but it was not statistically significant (RR 1.39, 95% CI 1.00-1.94) [19] . Similarly, when rivaroxaban was compared against warfarin patients that had >60% of INR readings within target range, the RR of major bleeding was 1.32 (95% CI 0.93-1.87) and a reduced dose of rivaroxaban, 15 mg per day, had no significant difference in major bleeding compared to warfarin [19] .
Edoxaban bleeding outcomes
Edoxaban was associated with a lower major bleeding incidence rate of 4% per year, compared with warfarin of 5.3% per year (HR 0.76, 95% CI 0.58-0.98), a lower composite of stroke, SE, major bleeding or all-cause mortality (HR 0.86, 95% CI 0.75-0.98), and a lower risk of all-cause mortality (HR 0.82, 95% CI 0.69-0.97) [24] .
D I S C U S S I O N
This systematic review synthesized the evidence for stroke and bleeding outcomes associated with DOACs compared with warfarin or aspirin in CKD and dialysis patients with AF. Of the 10 studies included, 6 were a sub-analysis of RCTs, 3 were retrospective cohort studies and 1 was a case-control study. The main results extrapolated from these 10 studies are as follows. (i) There was no significant difference between DOACs and warfarin for reducing stroke outcomes in moderate CKD patients, except for dabigatran 150 mg and apixaban, which was superior in reducing stroke or SE risk. (ii) In moderate CKD patients, edoxaban and apixaban had significantly reduced major bleeding outcomes (ISTH guidelines) [30] compared with warfarin, whereas rivaroxaban and dabigatran showed no difference. (iii)
There was no significant difference between DOACs and warfarin for reducing stroke outcomes in HD patients. (iv) In dialysis patients, rivaroxaban and dabigatran had an increased risk of major bleeding compared with warfarin, while there was no difference in major bleeding outcomes with apixaban compared to warfarin. (v) Apixaban significantly reduced stroke risk compared with aspirin in moderate CKD patients. (vi) Apixaban had no difference in major bleeding and all deaths compared to aspirin in moderate CKD patients. A table depicting these conclusions can be found in Supplementary Material Figure S3 .
Although the results of other meta-analyses on DOACs supported our results [31, 32] , this was the first systematic review to examine DOACs versus warfarin or aspirin with both moderate CKD patients and HD patients, specifically with AF. We identified six meta-analyses related to our review topic. Two of which studied only one of the four available DOACs [33, 34] ; three studied DOAC use in CKD patients for indications other than AF, such as venous thromboembolism and pulmonary embolism [34] [35] [36] . Unlike our systematic review, other recent meta-analyses excluded dialysis patients [31, 32, 37] , and patients with CrCl 25 mL/min. Other meta-analyses also only compared DOACs with warfarin use, whereas this review compared DOACs with warfarin or aspirin, thus allowing our review to include the CKD sub-analysis group of the AVERROES trial [19, 21] . Furthermore, these other meta-analyses had significant heterogeneity of the disease states included, DOACs examined and patient populations observed, hence the need for this systematic review.
The efficacy results of DOACs versus warfarin in moderate CKD patients demonstrated that dabigatran 150 mg reduced the risk of stroke or SE significantly more than warfarin [25] ; however, caution with dabigatran should be exercised due to the high renal elimination of this drug [38] . A pharmacokinetic study showed that a decrease in dose or increase in dosing interval may be needed in CKD patients because exposure to dabigatran is increased with renal impairment [39] . Therefore, with dabigatran accumulation in CKD patients there are potential safety concerns.
For moderate CKD patients there was no difference in stroke outcomes between dabigatran 110 mg twice daily [25] , rivaroxaban [28] and edoxaban [24] versus warfarin. Patients on apixaban had a lower baseline stroke risk (CHADS 2 score) than moderate CKD patients on rivaroxaban [23, 26, 28] , which may be an important reason for the preference of apixaban to rivaroxaban in both patients with normal kidney function and moderate CKD where apixaban showed greater reduction in stroke outcomes than warfarin [9, 23] . Even though one study showed that a comparable stroke risk reduction between apixaban and warfarin using the Cockcroft-Gault equation [23] , the CKD-EPI estimation of renal function is more accurate in estimating eGFR [40] . Therefore, our conclusions for this review were based on the CKD-EPI equation. Overall, patients with CKD have increased risk factors for stroke [2, 3] .
The safety results of this systematic review demonstrated that in moderate CKD patients, edoxaban and apixaban were associated with reduced major bleeding [23, 24] events, where rivaroxaban and dabigatran showed no significant difference in the incidence of major bleeding versus warfarin [25] [26] [27] [28] . One cohort study did demonstrate that rivaroxaban and dabigatran have significantly less major bleeding than warfarin; however, this study was conducted in a single center in Gwagju, South Korea [29] , so these results may not be widely generalizable.
In HD patients, there was no difference in stroke outcomes between apixaban [20] , dabigatran or rivaroxaban versus warfarin [19] . However, it is difficult to generalize these results, as both studies involving HD patients with AF were underpowered. There were only four patients that experienced an ischemic stroke on apixaban [20] , 11 embolic strokes on dabigatran [19] and eight on rivaroxaban [19] , which was too few to detect meaningful differences. HD patients had a greater baseline stroke risk than CKD patients [41] , which may be a reason for observing a reduced stroke risk with dabigatran 150 mg versus warfarin in CKD patients [25] , but showing equal efficacy in HD patients.
Rivaroxaban and dabigatran were associated with a higher risk of major bleeding in HD patients, defined as hemorrhagic event resulting in hospitalization or death [19] . Rivaroxaban demonstrated an increased major and minor bleeding event rate compared with warfarin [19] , despite a recent study showing the minimal impact of HD on the pharmacokinetics of rivaroxaban [42] . A possible explanation of increased risk of bleeding in HD patients compared with CKD patients on rivaroxaban and dabigatran is that there are many other causes of bleeding in HD patients. The increased bleeding risk reported may be due to dysfunction in coagulation, platelet secretion defects and plateletendothelial cell interaction problems, due to uremia [43, 44] , and heparin use during HD [43] . In HD patients not taking anticoagulants, baseline bleeding can be as high as 4.9/100 patient-years [45] . HD patients also have indirect factors that predispose them to bleeding such as anemia, erythropoietin deficiency and altered parathyroid hormone levels [2] . In patients with CrCl 25 mL/ min and patients on dialysis, there was no difference in major and composite bleeding outcomes of apixaban compared to warfarin. This may be because the study had a small sample size of 73 patients, and the HR and CI were not reported [20] . DOACs have varying degrees of renal clearance, with dabigatran demonstrating high renal elimination by HD [38] . Even though rivaroxaban and apixaban are minimally removed by HD [42, 46] , apixaban did not show the same increased major bleeding results as dabigatran and rivaroxaban [19, 20] . Apixaban is seemingly the safest DOAC in HD patients, showing equivalent major bleeding outcomes to warfarin and having the lowest renal excretion of the four DOACs [46] . However, even though a recent pharmacokinetic study in HD patients showed that apixaban 2.5 mg twice daily showed similar pharmacokinetic profile as 5 mg twice daily in patients with normal kidney function, this study did not assess long term clinical outcomes such as bleeding [47] .
It is not surprising that apixaban, a factor Xa inhibitor and more potent anticoagulant than aspirin, demonstrated significantly reduced stroke risk compared with aspirin in moderate CKD patients [21] . Therefore, based on efficacy outcomes alone, it is reasonable to recommend the use of apixaban over aspirin in moderate CKD patients.
Apixaban showed no difference in major bleeding compared to aspirin in moderate CKD patients [21] . The antiplatelet effects of aspirin may add to uremic gastrointestinal and hematological symptoms of CKD patients, therefore increasing bleeding sensitivity and prolonging bleeding times [48] . Therefore, since apixaban is more efficacious than aspirin, while demonstrating similar bleeding outcomes, apixaban has a seemingly better benefit to risk ratio than aspirin.
The major limitation to this review was the heterogeneity of the 10 included studies. Specifically, the studies included had varying definitions of major bleeding and stroke outcomes, and heterogeneous inclusion/exclusion criteria. Most of the trials, apart from three studies [19, 27, 29] that compared rivaroxaban and dabigatran with warfarin, compared only one DOAC with warfarin, as opposed to multi-arm trials. Further, each of the trials included had different definitions for renal dysfunction and dose adjustments for the DOACs varied in the studies. The only two studies done comparing DOACs with warfarin for AF in HD patients were included in our review, although both were retrospective cohort studies [19, 20] . Despite these limitations, analyzing the indirect comparisons will assist with clinical decision making in the absence of direct comparison evidence.
As demonstrated in a population study, rivaroxaban and dabigatran were associated with lower adverse renal outcomes such as decline in renal function and doubling of serum creatinine [49] . Even though there are a number of emerging studies evaluating renal outcomes of patients on DOACs [49] , our systematic review only evaluated stroke and bleeding risk. Renal outcome data is an important metric to follow up in future research.
There are two RCTs in progress that will greatly contribute to understanding DOAC use in HD patients with AF. These RCTs will evaluate stroke and/or bleeding outcomes of apixaban versus warfarin (or phenprocoumon) in this patient population [50, 51] , which will help with clinical decision making and generalizability, thus addressing some of the limitations of previous studies.
Our systematic review demonstrated that DOACs have equal efficacy compared to warfarin for reducing stroke outcomes in moderate CKD, except for dabigatran 150 mg and apixaban, which showed superior outcomes with reduced risk of stroke or SE. In moderate CKD patients, edoxaban and apixaban significantly reduced major bleeding events compared with warfarin, whereas rivaroxaban and dabigatran showed no difference. DOACs showed no significant difference in reducing stroke in HD patients. In HD patients, rivaroxaban and dabigatran were associated with an increased risk of major bleeding compared with warfarin, with apixaban showing no difference. Clinicians should continue to weigh the risk of stroke versus bleeding before prescribing DOACs in this patient population.
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